|dc.description.abstract||Objectives: This study will examine the expression of caspase-3 and apoptotic index (AI) in triple negative breast cancer (TNBC). By knowing the
non-responsiveness effect earlier, adverse effects of chemotherapy can be avoided.
Methods: This prospective cohort study has been approved by the local Ethics Committee. A total of 60 consent TNBC patients from Haji Adam Malik
General Hospital and Bunda Thamrin Hospital were included in the study. Patients with heart, kidney, liver disease, history of surgery, chemotherapy,
or hormonal therapy were excluded. Samples were analyzed immunohistochemically by monoclonal antibodies to assess caspase 3 and AI. Clinical
chemotherapy response is determined as a positive or negative response based on Response Evaluation Criteria in Solid Tumors.
Results: The results of this study indicated that caspase 3 was increased post-chemotherapy but could not predict the clinical response of
chemotherapy. Caspase-3 post-chemotherapy (5.27±1.27 pg/mL) compared to pre-chemotherapy (4.60±1.09 pg/mL) increased significantly
(p=0.003) by 0.67±1.66 pg/mL but no difference was found in AI score (p=0.819). Neither caspase 3 nor the AI were associated with a clinical
chemotherapy response (p=0.514 and p=0.993, subsequently).
Conclusion: Further research with larger samples is needed to determine the role and pathway of chemotherapy induced caspase 3 rise.||id